Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations
NCT05453903Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of bleximenib in acute myeloid leukemia (AML) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events, Number of Participants with Adverse Events by Severity and 1 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
bleximenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05453903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453903.